Previous 10 | Next 10 |
The American Association of Liver Diseases Annual Meeting, better known as The Liver Meeting, will open in Boston on Nov. 8. Data will be presented on new therapies for diseases ranging from hepatitis to non-alcoholic steatohepatitis (NASH), which affect hundreds of thousands, if not millions, o...
NEWARK, Calif., Oct. 14, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today a...
CymaBay Therapeutics (NASDAQ: CBAY ) will present two abstracts related to its seladelpar program for treating primary biliary cholangitis at The Liver Meeting in November. More news on: CymaBay Therapeutics, Inc., Healthcare stocks news, Read more ...
NEWARK, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY) today announced that two abstracts related to its seladelpar development program for the treatment of primary biliary cholangitis (PBC) will be presented at The Liver Meeting ® hosted by the Ame...
NEWARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today ...
NEWARK, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, announ...
NEWARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today ...
Introduction For two decades, the scientific advance of investigative drug candidates for PBC into clinical development seemed like an illusion. FDA approval of obeticholic acid (i.e. ocaliva) in 2016 as a breakthrough therapeutics developed by Intercept ( ICPT ) for patients with mild PBC...
The Addressable Market The addressable market for cholestatic chronic liver diseases, PBC and PSC, is not perceived to be very lucrative relative to that of NASH. However, therapeutics for PBC and PSC do have high pricing power due to their orphan designation status. Notably, the overall a...
Cymabay Therapeutics, Inc. (CBAY) Q2 2019 Earnings Conference Call August 07, 2019, 16:30 ET Company Participants Daniel Menold - VP, Finance Sujal Shah - President, CEO & Director Charles McWherter - SVP & Chief Scientific Officer Pol Boudes - Chief Medical Officer ...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
2024-03-12 10:45:01 ET UiPath Inc (PATH) PATH is trading UP for the last 5 days, and it at trading at $24.64 with volume of 4,269,666 and a one day change of $0.54 (2.25%). UiPath Inc has a 52-week low of 12.38 and a 52-week high of $27.87. The business's 50-day moving average price...